We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Reagent Red Cell Products Unveiled at Annual Blood Banking Meeting

By LabMedica International staff writers
Posted on 03 Nov 2014
Four new reagent red cell diagnostic products were unveiled at a blood banking meeting.

The annual meeting of the American Association of Blood Banks (AABB) that was held in Philadelphia, PA, USA from October 25–28, 2014, was selected for the launch of new red cell reagent diagnostic products produced by Quotient Limited (St Helier, Jersey).

The four new products are: (1) ALBAcyte Expanded Rh Negative Antibody Screen, (2) ALBAcyte Antibody Identification Panel (16-cell), (3) ALBAcyte Antibody Screen (two-cell), and (4) ALBAzyme Papain Solution Kit.

The ALBAcyte Expanded Rh Negative Antibody Screen will be of particular use with pregnant, Rh-negative women who have been treated with Rh immunoglobulin. More...
Its Rh-negative cells detect all the unexpected antibodies required of traditional screens. The ALBAcyte Antibody Identification Panel (16-cell) is a full antibody identification panel with six complementary cells. The ALBAcyte Antibody Screen (two-cell) is a robust antibody screen for those laboratories that prefer a two-cell screen, or frequently test pediatric or other small-volume samples. Red cells incorporated in this product have been carefully selected to maximize homozygosity, thus optimizing the detection of antibodies. The ALBAzyme Papain Solution Kit is a kit combining both papain and enzyme control, which pairs with the existing papain-treated ALBAcyte Antibody Identification Panel (10-cell), to better allow laboratories to treat and test auto-controls and patient samples.

"These four new products expand our reagent red cell offering, including the addition of a number of novel products," said Jeremy Stackawitz, president of Quotient Limited. "Quotient's product offering can now address all the needs of the vast majority of blood bank laboratories, truly making it a one-stop-shop for reagent red cells."

Related Links:
Quotient Limited



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.